Azilect (rasagiline) slows the progression of Parkinson’s disease.

This has been a burning question with MAO-B inhibitors for years...first with selegiline and now with Azilect.

Azilect gives us a glimmer of hope...because a single industry-sponsored study suggests that 1 mg/day might slow disease progression.

But that same study shows that 2 mg/day doesn’t help. This has many experts questioning whether 1 mg/day really works...because it doesn’t make sense that a higher dose wouldn’t work when a lower dose does.